Catherine Broome, MD
Hematology & Oncology · Washington, DCNPI 1669470985
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Sanofi at 37.1% of the total. Among hematology & oncology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $1838.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$187K
- AstraZeneca$164K
- Recordati_rare_diseases_inc.$63K
- Argenx US, Inc.$28K
- Bioverativ Therapeutics Inc.$21K
- Sanofi US Services Inc.$14K
- plus $27K from 9 others
Across 245 payments — averaging $10,366 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bioverativ Therapeutics Inc.$911K
- Argenx US, Inc.$305K
- Sanofi US Services Inc.$305K
- Rigel Pharmaceuticals, Inc.$285K
- Acerta Pharma LLC$205K
- Novartis$121K
- plus $407K from 9 others
What the payments were for
- Consulting fees$268,07553%
- Speaking & faculty fees$170,95334%
- Travel & lodging$61,38312%
- Food & beverage$3,3521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 80 | $186,867 |
| AstraZeneca | 96 | $163,769 |
| Recordati_rare_diseases_inc. | 25 | $63,468 |
| Argenx US, Inc. | 32 | $28,070 |
| Bioverativ Therapeutics Inc. | 22 | $21,023 |
| Sanofi US Services Inc. | 1 | $13,500 |
| Sanofi-aventis U.S. LLC | 5 | $8,854 |
| Novartis | 3 | $6,750 |
| Janssen Scientific Affairs, LLC | 3 | $4,480 |
| Janssen Global Services, LLC | 1 | $3,375 |
| Incyte Corporation | 1 | $2,460 |
| Biocryst Pharmaceuticals, Inc. | 2 | $1,080 |
| AbbVie | 1 | $35 |
| Johnson & Johnson | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$503,763 in reported general payments places this provider in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 93 | $1,300,005 |
| ImbruvicaIbrutinib | 52 | $736,140 |
| PromactaEltrombopag Olamine | 16 | $323,549 |
| BrukinsaZanubrutinib | 16 | $246,007 |
| VenclextaVenetoclax | 12 | $185,765 |
| EliquisApixaban | 48 | $60,531 |
| XareltoRivaroxaban | 32 | $48,573 |
| Fondaparinux Sodium | 12 | $20,047 |
| Hydromorphone Hcl | 30 | $753 |
| Hydroxyurea | 22 | $727 |
| Warfarin Sodium | 15 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $163,769 | $1,300,00593 claims |
| NovartisPromacta | $6,750 | $323,54916 claims |
| AbbVieVenclexta | $35 | $185,76512 claims |
| Johnson & JohnsonXarelto | $16 | $48,57332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
- Faysal HarounWashington$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.